(Q33761680)

29 July 2017

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

29 July 2017

0 references

1 reference

1 reference

Munechika Enjoji

1

1 reference

29 July 2017

Kazuyuki Machida

2

1 reference

29 July 2017

Motoyuki Kohjima

3

1 reference

29 July 2017

Masaki Kato

4

1 reference

29 July 2017

Kazuhiro Kotoh

5

1 reference

29 July 2017

Kazuhisa Matsunaga

6

1 reference

29 July 2017

Manabu Nakashima

7

1 reference

29 July 2017

Makoto Nakamuta

8

1 reference

29 July 2017

12 March 2010

1 reference

Lipids in Health and Disease

29 July 2017

1 reference

29 July 2017

9

1 reference

29 July 2017

29

1 reference

https://scigraph.springernature.com/pub.10.1186/1476-511x-9-29

29 July 2017

0 references

cites work

Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Nonalcoholic fatty liver disease

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Autoregulation of the human liver X receptor alpha promoter

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease.

22 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Clinical and pathological features of non-alcoholic steatohepatitis.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2847569

Reduced hepatic expression of adipose tissue triglyceride lipase and CGI-58 may contribute to the development of non-alcoholic fatty liver disease in patients with insulin resistance

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20222991

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20222991

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1476-511X-9-29

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference